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ABSTRACT
Osteogenesis imperfecta (OI) is a genetic bone dysplasia characterized by osteopenia and easy susceptibility to fracture. Symptoms are
most prominent during childhood. Although antiresorptive bisphosphonates have been widely used to treat pediatric OI, controlled
trials show improved vertebral parameters but equivocal effects on long-bone fracture rates. New treatments for OI are needed to
increase bone mass throughout the skeleton. Sclerostin antibody (Scl-Ab) therapy is potently anabolic in the skeleton by stimulating
osteoblasts via the canonical wnt signaling pathway, and may be beneficial for treating OI. In this study, Scl-Ab therapy was investigated
in mice heterozygous for a typical OI-causing Gly!Cys substitution in col1a1. Two weeks of Scl-Ab successfully stimulated osteoblast
bone formation in a knock-in model for moderately severe OI (Brtl/þ) and in WT mice, leading to improved bone mass and reduced
long-bone fragility. Image-guided nanoindentation revealed no alteration in local tissue mineralization dynamics with Scl-Ab. These
results contrast with previous findings of antiresorptive efficacy in OI both inmechanism and potency of effects on fragility. In conclusion,
short-term Scl-Ab was successfully anabolic in osteoblasts harboring a typical OI-causing collagen mutation and represents a
potential new therapy to improve bone mass and reduce fractures in pediatric OI.  2013 American Society for Bone and Mineral
Research.
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Introduction
Osteogenesis imperfecta (OI), or ‘‘brittle bone disease,’’ isa heritable disorder caused predominantly by mutations
in type I collagen or in proteins that promote the folding or
posttranslational modification of collagen. Patients with OI have
increased bone fragility and are susceptible to fracture from
minimal force, skeletal deformities, and growth deficiency. OI
fragility symptoms are generally most prominent in children; the
disorder ranges in severity frommild forms with slightly elevated
fracture risk to perinatal lethality.(1)
Current treatment options for OI focus on antiresorptive
bisphosphonates (BPs), which have been shown effective
at increasing vertebral areal bone mineral density (BMD) and
height in clinical trials. However, BP effects in long bones are
less evident, and most pediatric OI trials observe little or no
functional benefit.(2–6) Moreover, whereas BP therapy has been
generally well tolerated in pediatric OI patients, there are
concerns about long-term retention of BPs in the skeleton and
use in a growing population.(7)
Sclerostin antibody (Scl-Ab) is a novel anabolic bone thera-
peutic presently in clinical trials for treatment of osteoporosis.(8)
Sclerostin is secreted primarily by osteocytes and negatively
regulates bone formation by binding to the LRP4/5/6 complex,
inhibiting anabolic canonical wnt signaling in osteoblasts.(9–11)
As a result, treatment with a neutralizing Scl-Ab reduces
sclerostin inhibition of canonical wnt signaling and is highly
anabolic in preclinical models and in a phase 1 clinical trial of
men and postmenopausal women.(8,12,13) Whether Scl-Ab therapy
is capable of stimulating osteoblast activity in cells harboring a
typical OI-causing mutation has yet to be demonstrated.
The Brtl/þ mouse is a knock-in model for moderately severe
Type IV OI with a G349C point mutation on col1a1 that recreates
an identical defect found in an OI patient.(14) The Brtl/þ mouse
recapitulates multiple features of the observed clinical pheno-
type, including smaller size, reduced BMD, more severe
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phenotype at young ages, increased bone brittleness, and
increased bone turnover,(15,16) making it an appropriate model
for testing the anabolic efficacy of Scl-Ab in OI. The purpose of
this study was to determine whether a short-term intervention
with Scl-Ab in the Brtl/þ model of OI would be effective
at stimulating an anabolic skeletal response and improving
long-bone strength.
Materials and Methods
Animals
Wild-type (WT) and Brtl/þ mice are maintained on a mixed
background of Sv129/CD-1/C57BL/6S, and all Brtl/þ animals
were the product of breeding male Brtl/þ mice with female WT
mice. Eight-week-old male WT and Brtl/þ mice were randomly
assigned to Scl-Ab (Scl-AbIV; Amgen, Thousand Oaks, CA, USA)
treatment or vehicle (Veh) injection (PBS) with n¼ 7/group.
Sclerostin antibody was injected subcutaneously at 25mg/kg,
two times per week, for 2 weeks. Calcein (30mg/kg) was injected
at the start of experiment, after 1 week, and 1 day prior to
sacrifice by intraperitoneal injection to facilitate dynamic histo-
morphometry and nanoindentation placement. Body weights
were recorded with each injection. Blood samples were collected
at euthanasia by intracardiac puncture, and serumwas separated
by centrifuge and stored at 808C until analyzed by ELISA.
Left femurs were collected for micro–computed tomography
(mCT) and mechanical testing, and right femurs were collected
for dynamic histomorphometry and nanoindentation tests. Both
were stored at 208C in lactated Ringer’s solution (LRS)-soaked
gauze until testing or further specimen preparation. All protocols
and procedures involving animals were approved by the
University of Michigan’s Committee on Use and Care of Animals.
Serum markers
To measure osteoblast activity, serum osteocalcin (OCN) was
quantified with a commercially available ELISA kit (BT-470; BTI,
Stoughton, MA, USA). To quantify osteoclast number, serum
TRACP5b was measured with a commercially available solid-
phase immunofixed enzyme activity assay (MouseTRAP; IDS,
Fountain Hills, AZ, USA). Both serum tests were performed in
duplicate.
mCT
Left femora were scanned in water using cone beam CT (eXplore
Locus SP; GE Healthcare Pre-Clinical Imaging, London, ON,
Canada). Scan parameters included a 0.5-degree increment
angle, 4 frames averaged, an 80-kVp and 80-mA X-ray source with
a 0.508-mm Al filter to reduce beam hardening artifacts, and a
beam flattener around the specimen holder.(17) All images were
reconstructed and calibrated at an 18-mm isotropic voxel size to
a manufacturer supplied phantom of air, water, and hydroxyap-
atite. Regions of interest (ROI) were located for both cortical and
trabecular parameters. A diaphyseal cortical region of interest
(ROI) spanning 15% of total femur length was located midway
between the distal growth plate and third trochanter. Cortical
bone was isolated with a fixed threshold of 2000 Hounsfield units
(HU) for all experimental groups. Parameters including cortical
thickness, cross sectional area, tissue mineral density (TMD),
anterior-posterior bending moment of inertia, endosteal perim-
eter, and periosteal perimeter were quantified with commercially
available software (MicroView v2.2 Advanced Bone Analysis
Application; GE Healthcare Pre-Clinical Imaging, London, ON,
Canada). A trabecular ROI 10% of total femur length was located
immediately proximal to the distal femoral growth plate and
defined along the inner cortical surface with a splining algorithm.
Due to the large differences in morphology induced by Scl-Ab
treatment, a fixed threshold could not be utilized without
bias. Trabecular metaphyseal bone was isolated with a more
conservative autothresholding algorithm for each specimen
based on the bimodal distribution between marrow and
bone.(18) Parameters including bone volume fraction (BV/TV),
trabecular thickness (TbTh), and trabecular number (TbN) were
quantified using standard stereology algorithms (MicroView
v2.2). A 3D sphere-fitting algorithm was also used to confirm the
stereology data for TbTh.(19)
Mechanical testing (whole bone)–four-point bending
Following mCT scanning, left femora were loaded to failure in
four-point bending using a servohydraulic testing machine (MTS
858; MiniBionix, Eden Prairie, MN, USA). All specimens were kept
hydrated in LRS-soaked gauze until mechanical testing. In the
same mid-diaphyseal region analyzed by mCT, the mid-diaphysis
was loaded in four-point bending with the posterior surface
oriented under tension. The distance between the wide, upper
supports was 6.26mm, and the span between the narrow, lower
supports 2.085mm. The vertical displacement rate of the four-
point bending apparatus in the anterior-posterior direction was
0.5mm/s. Force was recorded by a 50-lb load cell (Sensotec,
Columbus, OH, USA) and vertical displacement by an external
linear variable differential transducer (LVDT; Lucas Schavitts,
Hampton, VA, USA), both at 2000 Hz. A custom MATLAB script
was used to calculate stiffness, yield load, yield displacement,
ultimate load, failure displacement, post-yield displacement, and
energy to failure. Combining anterior-posterior bending mo-
ment of inertia data from mCT with mechanical stiffness from
four-point bending, the estimated elastic modulus was calculat-
ed using standard beam theory as described.(15)
Mechanical testing (tissue level)–fluorescent-guided
nanoindentation
Right femora were dehydrated, encased in epoxy (Kold Mount;
Vernon-Benshoff, Albany, NY, USA), and cut transversely at the
mid-diaphysis with a low-speed saw (IsoMet; Beuhler, Lake
Bluff, IL, USA). The distal section of tissue was polished using
progressive grades of silicon carbide abrasive paper (1200-,
2400-, and 4000-grit) under water irrigation for 2 minutes at each
grade. To further decrease surface roughness, the encased
specimens were polished on a felt pad for 5 minutes with a
0.25-mm diamond suspension (Struers Inc., Cleveland, OH, USA).
Specimens were then ultrasonically cleansed in a water bath for
10 minutes to remove surface debris, and glued to magnetic
specimen plates for nanoindentation testing. The final root
mean square (RMS) roughness of the specimens’ surface was
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10.0 3.7 nm, as assessed with scanning probe microscopy of a
5-mm 5-mm region of the posterior mid-cortex.
A custom 950 TI TriboIndenter (Hysitron, Minneapolis,
MN, USA) instrumented with a fluorescent light-source and
fluorescein isothiocyanate (FITC) filter allowed for simultaneous
visualization of calcein labeling in specimens and accurate
positioning of indents to locations matched for tissue age
and treatment status with 0.5-mm spatial resolution. Four
ROIs were mechanically tested in the posterior aspect of the
femoral cross section: the mid-cortex (defined as midway
between the first calcein label on the periosteal and endosteal
surfaces, if any); along the first calcein label on 15-day-old bone;
along the second calcein label on 8-day-old bone; and along the
third and outer calcein label along 1-day-old bone. Indentation
consisted of loading a diamond Berkovich indenter tip (Hysitron,
Minneapolis, MN, USA) into samples at 300mN/s, holding
at a maximal load of 3000mN for 10 s, and unloading at
300mN/s. The indentation modulus E was calculated from
the load-displacement curves using the standard Oliver-Pharr
method.(20) Eight indents, 10mm apart, were made along each
calcein label and the mid-cortex, with values averaged for each
site and mouse.
Dynamic histomorphometry
Using the same specimens tested by nanoindentation, dynamic
histomorphometry was performed at the mid-diaphysis on the
first and third labels according to standard nomenclature.(21)
Briefly, fluorescent images were acquired using a Zeiss Axiovert
200M inverted microscope equipped with Apotome imaging
system to minimize out-of-plane light, negating the need
for thin sections. Fluorescent images were taken with a 10
objective of calcein (excitation 485/20 nm, emission: 540/25 nm)
labels in bone. The 10 images of the cortex were merged into
a single image (PhotoShop; Adobe, Inc.), and these merged
images were analyzed using commercially available software
(Bioquant Osteo v7.20.10; Bioquant, Nashville, TN, USA). Bone
surface (BS), mineral apposition rate (MAR), mineralizing surface
to bone surface (MS/BS), and bone formation rate (BFR)
were quantified.
Statistics
Based on previous studies examining the phenotype of Brtl/þ at
8 weeks of age(15) and on the therapeutic effects of BP in
Brtl/þ,(16) a power analysis suggests that samples sizes of seven
per genotype per group would sufficiently detect a therapeutic
response equivalent to that of alendronate after 12 weeks of
therapy. A multivariate ANOVA with least significant difference
(LSD) post hoc was used to make all comparisons with the
exception of nanoindentation data. For nanoindentation data
along calcein labels, a repeated measures ANOVA was used with
genotype and treatment status as between-subjects factors and
tissue age as the within-subjects factor with simple contrasts
to mid-cortical reference values. In all cases, p< 0.05 was
considered significant. All data is presented as mean SD.
Results
Body weight and bone length remain unchanged with
short-term Scl-Ab treatment
Consistent with the reduced body size with OI, body weight was
significantly lower in male Brtl/þ (25.4 1.8 g) compared tomale
WT mice (30.4 2.8 g) at 8 weeks of age. Twice-weekly dosing of
these mice with 25mg/kg Scl-Ab for 2 weeks did not significantly
change body weight gains (data not shown). Scl-Ab treatment
also had no effect on femoral length in WT mice (15.9 0.6mm
Veh versus 16.0 0.5mm Scl-Ab) or the shorter Brtl/þ mice
(15.2 0.4mm Veh versus 15.5 0.4mm Scl-Ab) after 2 weeks.
Serum markers show Brtl/þ anabolic response to Scl-Ab
Untreated Brtl/þ animals showed marginally elevated serum
osteocalcin (p¼ 0.060) and serum TRACP5b (p¼ 0.083) relative
to WT (Fig. 1), consistent with reported increases in Brtl/þ bone
turnover.(16) Scl-Ab therapy significantly increased serum
osteocalcin in both WT and Brtl/þ (Fig. 1), demonstrating a
rapid systemic anabolic response to therapy. Scl-Ab yielded
trends toward reduced levels of serum TRACP5b in both WT
(p¼ 0.10) and Brtl/þ (p¼ 0.082) mice, consistent with published
Fig. 1. Serum OCN (A) is elevated and serum TRACP5b (B) is reduced with Scl-Ab therapy in both WT and Brtl/þ, suggesting a decoupled effect on bone
formation and bone resorption. In vehicle-treated animals, Brtl/þ trends toward higher OCN levels in A and TRACP5b levels in B, suggesting increased
bone turnover in Brtl/þ. p< 0.05 Scl-Ab versus Veh, þp< 0.05 Brtl/þ Scl-Ab versus WT Veh.
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reports observing reduced serum markers of bone resorption in
rats and humans.(8,12)
Scl-Ab differentially increases cortical bone formation in
Brtl/þ and WT
At the femoral mid-shaft, Scl-Ab treatment increased periosteal
BFR/BS in Brtl/þ and WT animals by 76% and 108%, respectively
(Fig. 2). In Brtl/þ, these increases were caused by a 50% increase
in MS/BS, with no significant improvement in MAR. Conversely,
WT improvements in BFR/BS resulted from a significant 76%
increase in MAR with no significant change in MS/BS.
Scl-Ab increases trabecular bone apposition on existing
bone surfaces
Brtl/þ animals have lower BV/TV relative to WT caused by
reduced trabecular number, but not thickness (Fig. 3). Scl-Ab
significantly increased distal femoral metaphyseal BV/TV in WT
animals with a trend in Brtl/þ (p¼ 0.077). These improvements
resulted from significant increases in trabecular thickness in
both WT and Brtl/þ , with no change in trabecular number in
either genotype.
Cortical shape and size, not mineralization, are increased
with Scl-Ab
At the femoral mid-diaphysis, Brtl/þ animals have a reduced
cortical thickness and area relative to WT as measured by mCT
(Table 1). Scl-Ab treatment significantly increased both cortical
thickness and area in Brtl/þ and WT, primarily through increased
femoral cortical periosteal perimeter. Moreover, Scl-Ab treat-
ment of Brtl/þ restored cortical thickness and area to levels not
significantly different from WT Veh. Endocortical perimeter
showed no significant differences with Scl-Ab treatment in
either WT or Brtl/þ. In combination, these individual factors
contributed to increasing trends in the anterior-posterior
bending moment of inertia with Scl-Ab treatment in both WT
and Brtl/þ , reflecting a structurally stronger bone. Mean cortical
tissue mineralization (TMD) calculated by mCT was unaffected by
Scl-Ab in either WT or Brtl/þ.
Sclerostin antibody improves whole-bone mechanical
properties
Brtl/þ femora have inherently lower ultimate load and stiffness
(p¼ 0.063) compared to WT (Table 1). Two weeks of Scl-Ab
treatment significantly increased ultimate load and stiffness in
both WT and Brtl/þmice. Importantly, Scl-Ab treatment of Brtl/þ
improved functional outcomes including ultimate load and
stiffness to levels not significantly different from WT Veh,
suggesting that the phenotypic deficit was rescued by therapy.
The estimated tissue elastic modulus, as calculated by standard
beam theory, was not affected by Scl-Ab treatment in WT or
Brtl/þ , corroborating similar findings in TMD.
A hallmark feature of OI bone is increased tissue brittleness.
Postyield displacement (PYD) during four-point bending is a
measure of ductility, an inverse indicator of material brittleness.
Phenotypically, although Brtl/þ PYD was not significantly
Fig. 2. Dynamic histomorphometry at the periosteal femoral mid-diaphysis reveals anabolic effect of Scl-Ab in WT and Brtl/þ. Femoral cortical mid-
diaphyseal periosteal BFR (A) increases with Scl-Ab are a result of increased periosteal MAR (B) in WT and periosteal MS/BS (C) in Brtl/þ. Brtl/þ Veh, n¼ 6;
all other groups n¼ 7. p< 0.05 Scl-Ab versus Veh, þp< 0.05 Brtl/þ Scl-Ab versus WT Veh.
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different than WT, five out of seven WT samples had a PYD
greater than the largest Brtl/þ PYD value, consistent with
previous reports of increased brittleness at a similar age.(15)
Unexpectedly, PYD was increased 324% with Scl-Ab in WT
(p< 0.05) and 58% with Scl-Ab in Brtl/þ , although failing to
achieve statistical significance due to high variability. These data
suggest Scl-Ab reduced bone brittleness, improving bone
ductility in both Brtl/þ and WT.
Nanoindentation reveals similar patterns of
mineralization in Scl-Ab–treated animals
Nanoindentation measures local micromechanical properties
associated with local tissue mineralization by measuring the
tissue elastic modulus. Phenotypically, in the overall statistical
model, genotype was a significant predictor, suggesting a
greater tissue elastic modulus in Brtl/þ compared to WT.
However, comparisons between genotypes at specific tissue
ages were not significant. Nanoindentation revealed that Scl-Ab
treatment did not change the tissue elastic modulus of bone in
either WT or Brtl/þ. This indicates that despite the sudden
change in osteoblastic anabolic function with Scl-Ab treatment,
no differences in tissue elastic modulus were seen in bone grown
under the influence of Scl-Ab (Fig. 4). The tissue age at which
newly formed bone achieved mature tissue elastic modulus was
rapid, as only bone laid down 1 day prior to euthanasia had a
significantly reduced elastic modulus relative to mid-cortical
values consistent with the rapid establishment of mechanical
properties which has been reported in rats.(22,23) No difference
was found between 2-week-old bone and 1-week-old bone
relative to mid-cortical values.
Discussion
In this study, mice with a genetic knock-in that recreates a typical
OI-causing mutation in type I collagen showed a positive
response following short-term Scl-Ab therapy. Two weeks of Scl-
Ab significantly improved bone mass at both cortical and
trabecular sites, and significantly reduced long bone fragility.
In the context of existing anabolic and antiresorptive treatment
options, Scl-Ab is novel and has high potential as a therapeutic
for OI patients. Current anabolic treatment options have not
shown uniform success when applied to OI. The anabolic bone
agent teriparatide is currently approved as an osteoporosis
therapy, but has been associated with osteosarcoma after long-
term treatment in growing rats,(24) and is therefore contra-
indicated for use in children with open growth plates. Growth
hormone has also been implemented as an anabolic therapy for
OI. Although effective in some patients at increasing BMD as well
as improving bone histomorphometry, the benefits are selective
for patients who respond to recombinant human growth
hormone (rGH) with increased linear growth. Other OI patients
treated with rGH experience no positive effect, and may
exacerbate their existing low bone mass phenotype by
increasing osteoclast surface.(25)
As a result of limited anabolic therapeutics, antiresorptive BPs
have been widely used in OI. Several controlled pediatric OI
clinical trials have demonstrated that BP treatment is effective at
increasing vertebral BMD.(2–6) Functionally, intravenous BPs are
effective at increasing vertebral height, an indirect indicator of
bone strength that suggests increased resistance to compres-
sion.(3,4) However, in long bones a functional benefit is less clear,
even in controlled trials of up to 125 patients.(1–6)
Although BP therapy increases areal BMD in pediatric OI
populations, recent evidence suggests potential for several
undesirable effects intrinsic to the BP mechanism of action. First,
BP binds strongly to the skeleton and has been detected in
urinary markers 8 years after cessation of treatment, resulting in
long-term suppression of bone turnover.(26) Long-term BP
therapy has been associated with the accumulation of micro-
damage in several animal models.(27–31) Brtl/þ mice have an
increased propensity to form and accumulate microdamage(32)
and thus BP treatment may potentially exacerbate this effect.
During growth, antiresorptive therapy results in retention of
calcified cartilage near the growth plates. This retention of
primary spongiosa manifests radiographically as sclerotic
Fig. 3. mCT of the distal femur metaphysis reveals anabolic changes with
Scl-Ab therapy. BV/TV (A) and Tb.Th (B) were improved by Scl-Ab with no
effect on Tb.N (C). (D–G) Representative mCT images of distal metaphy-
seal trabecular bone reflect these changes. For each experimental group,
the animal with the median BV/TV value is shown. A conservative
specimen specific threshold is applied as described in Materials and
Methods. p< 0.05 Scl-Ab versus Veh; #p< 0.05 WT Veh versus Brtl/þ
Veh; þp< 0.05 Brtl/þ Scl-Ab versus WT Veh.
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metaphyseal banding, coinciding with each BP treatment cycle,
and these changes can bias measured BMD gains(33) without
concomitant improvements in strength. Previous studies of BP
treatment in Brtl/þ found increased trabecular number, but not
thickness.(33) Notably, in the present study with Scl-Ab, gains
in trabecular bone mass resulted from increased trabecular
thickness, not number.
In this study, we found that unlike WT osteoblasts, Brtl/þ
osteoblasts did not increase their MAR with Scl-Ab treatment.
This lack of an MAR increase in Brtl/þ may be suggestive of
defective osteoblasts unable to keep pace with Scl-Ab–induced
bone formation demands. In support of this, Brtl/þ mice
demonstrate a mild delay in secretion of collagen in cell culture,
and an enlarged endoplasmic reticulum (ER) has been observed
in Brtl/þ fibroblasts, suggesting ER-stress correlated with
collagen production, and possibly degradation of mutant
collagen.(34) As a consequence, Brtl/þ may respond to short-
term Scl-Ab by increasing mineralizing surface, and thus
osteoblast recruitment, rather than individual cellular activity.
This increase in mineralizing surface still leads to a significant
increase in overall BFR, resulting in the improved bone size and
strength observed. Whether this result also exists in the various
OI mouse models with different mutations will be important to
contrast with the data presented here. Alternatively, animal age
and treatment duration of the Brtl/þ mouse model used in this
study may also modulate any Scl-Ab–induced MAR effect.
Preliminary data from Brtl/þmice treated for 5 weeks with Scl-Ab
suggest a similar increase in MAR in both WT and Brtl/þ
animals.(35) Whereas a significant increase in periosteal perimeter
was found in Brtl/þ when treated with sclerostin antibody, no
significant differences were observed on the endosteal surface.
This contrasts with previous findings of female rats treated with
sclerostin antibody following ovariectomy, where a dominant
treatment effect was observed on the endosteal bone surface.(12)
This may suggest a differential response of periosteal versus
endosteal surface to Scl-Ab, dependent on animal age or
hormonal status, reflecting either altered cell response to drug or
differential bioavailability at these sites.
Consistent with previous studies of linear growth with Scl-Ab
or in male SOST knockout mice,(36,37) we found no differences in
Table 1. Cortical mCT and Mechanical Properties
WT Veh WT Scl-Ab Brtl Veh Brtl Scl-Ab
Cortical mCT
Thickness (mm) 0.21 0.01 0.24 0.01 0.17 0.02# 0.20 0.02
Cross-sectional area (mm2) 1.01 0.10 1.16 0.10 0.76 0.10# 0.91 0.10
Endosteal perimeter (mm) 4.51 0.36 4.43 0.22 4.09 0.13# 4.21 0.18þ
Periosteal perimeter (mm) 5.80 0.42 5.95 0.32 5.15 0.16# 5.48 0.21 (p¼ 0.06)
Bending moment of inertia (mm4) 0.21 0.05 0.23 0.04 0.12 0.03# 0.16 0.03 (p¼ 0.08, p¼ 0.06)
Tissue mineral density (mg/cm3) 1052 43 1051 50 1081 39 1092 41 (n.s., p¼ 0.1)
Mechanical four-point bending
Ultimate load (N) 27.1 4.5 38.7 10.2 18.2 5.0# 26.8 7.8
Stiffness (N/mm) 237 28 297 66 192 35 (p¼ 0.063) 256 33
Energy to failure (J) 3.1 1.6 10.6 7.6 1.0 0.6 2.0 1.1
Post-yield displacement (mm) 0.058 0.049 0.247 0.143 0.026 0.021 0.041 0.037
Estimated elastic modulus (GPa) 4.6 1.2 4.8 0.5 6.0 1.2# 6.0 0.7þ
Femoral mid-diaphyseal cortical microCT and mechanical four-point bending data.
mCT¼micro–computed tomography; WT¼wild-type; Veh¼ vehicle; Scl-Ab¼ sclerostin antibody.
p< 0.05 Scl-Ab versus Veh.
#p< 0.05 WT Veh versus Brtl/þ SclAb.
þp< 0.05 Brtl/þ SclAb versus WT Veh.
Fig. 4. Nanoindentation was performed along calcein labels to match
tissue age between treated and untreated animals. (A) White light, FITC,
and merged images showing placement of indents. Nanoindentation
revealed no difference in tissue elastic modulus across treatment groups
in WT (B) and Brtl/þ (C). Significance relative to mid-cortical reference
and denotes p< 0.05.
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either femur length or body mass, suggesting that longitudinal
growth modulation is less sensitive than periosteal growth after
2 weeks of therapy. Unexpectedly, we found that Scl-Ab
significantly reduced bone brittleness (increased PYD) in WT
animals as measured by whole-bone mechanical four-point
bending. Although reductions in bone brittleness were not
statistically significant in Brtl/þ animals in this study, our finding
of reduced brittleness in WT has broader implications about
bone quality changes associated with Scl-Ab treatment.
Although the differing bone geometries induced by Scl-Ab
treatment raises the potential for experimental bias, the large
magnitude of our observed difference in WT (324% increase
in PYD) remains suggestive. In contrast to the Scl-Ab data
presented here, previous BP treatment in Brtl/þ found neither
significant changes nor increasing trends in PYD. Moreover, BP-
treated WT showed marginal reductions in PYD, reflecting no
improvements in bone brittleness with BPs despite large gains in
femoral bone mass.(33) Interestingly, in the contralateral femurs
of the same animals which demonstrated reductions in PYD, we
did not observe any difference in the elastic modulus of bone
formed under the influence of Scl-Ab by fluorescence-guided
nanoindentation. These findings represent the first tissue-level
mechanical test of bone formed during Scl-Ab treatment
through coupling of fluorescent imaging to nanoindentation.
Further studies are required to determine postyield behavior of
bone at the tissue level, unlike those reported in this study.
The primary goals of this study were to demonstrate
the potential for Scl-Ab efficacy at inducing an osteoblast
response in Brtl/þ at an age that has been well characterized
(8 weeks).(15,16) Although clinical efficacy will likely require an
earlier onset of therapy and longer duration, these findings of
significantly improved cortical bonemass, stiffness, and breaking
loads with such a short duration of therapy are encouraging,
particularly given the mixed response of BP efficacy at cortical
sites.(2–6) Thus, these findings support further exploration of
Scl-Ab at earlier ages and for longer duration in treatment of OI.
In this study, Scl-Ab rapidly increased bone formation,
resulting in increased cortical and cancellous bone volume
and cortical bone strength without altering bone mineralization
kinetics. Whereas Brtl/þ and WT both responded favorably to
Scl-Ab, it is unknown if there are differences in sclerostin
expression in OI patients or OI mousemodels throughout growth
that could modulate the therapeutic effect. More broadly, as
sclerostin mediates the Wnt signaling pathway, any phenotypic
differences existing in Brtl/þ , including the receptors LRP4/5/6,
competing ligands including DKK1, or regulation of b-catenin
signaling may determine the skeletal Scl-Ab response.
Furthermore, it should be recognized that some Scl-Ab studies
have found a decrease in bone resorption outcomes.(8,12) Given
that an upregulation in bone resorption is phenotypic of OI along
with the trends of reduced serum TRACP5b data with Scl-Ab from
this study, the osteoclast response will be explored in greater
detail in future studies with longer-term therapy. Nevertheless,
the trabecular mCT data in this study shows a large increase in
trabecular thickness with no change in trabecular number and is
suggestive of a dominantly osteoblast-mediated effect.
In summary, we have demonstrated that 2 weeks of Scl-Ab
therapy was capable of increasing bone formation rate in cells
harboring a classical OI-causing Gly!Cys substitution in col1a1.
These gains lead to improved bone mass and whole-bone
mechanical properties without altering the timing of tissue
mineralization. Although BP therapy is in widespread use for
pediatric OI patients, there is pressing need for more effective
anabolic therapeutics to improve patient outcomes. Scl-Ab is a
unique and promising anabolic therapy that may be particularly
useful for the treatment of pediatric OI. The present data suggest
Scl-Ab may be beneficial for the treatment of OI patients by
stimulating the osteoblasts and reducing fracture risk.
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